La Prensa Medica.ISSN: 0032-745X

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Dasatinib Monotherapy to Maintain Complete Remission before Allogeneic Bone Marrow Transplantation under Monitoring of the Blastic Chronic Myelogenous Leukemia Biphenotypic Cells and Bcr-Abl Transcripts

Dasatinib Monotherapy to Maintain Complete Remission before Allogeneic Bone Marrow Transplantation under Monitoring of the Blastic Chronic Myelogenous Leukemia Biphenotypic Cells and Bcr-Abl Transcripts

A 49-year-old male with blastic phase chronic myelogenous leukemia (CML-BP) with CD13/CD19 double-positive markers was treated with a combination of tyrosine kinase inhibitors and chemotherapy, followed by allogeneic bone marrow transplantation (allo-BMT). The biphenotypic cells and bcr-abl transcripts were monitored during the treatment course, and the efficacy of dasatinib for the treatment of the allo-BMT eligible CML-BP patient was evaluated. Following a single course of hyper-CVAD/MA with imatinib mesylate, the biphenotypic cells and bcr-abl mRNA decreased gradually, and hematological complete remission (CR) was achieved. Thereafter, dasatinib maintained the CR without any adverse events for four months. The allo-BMT was conducted successfully. Although minimal residual disease was apparently observed at the time of allo-BMT, bcr-abl mRNA became undetectable by nested realtime polymerase chain reaction (PCR) one month after the allo- BMT. Thus, dasatinib monotherapy is feasible for maintaining the remission of CML-BP for at least a short duration before allo-BMT.

Special Features

Full Text

View

Track Your Manuscript

Recommended Conferences

Share This Page

Media Partners

Associations